Phase I clinical trial of namitecan (ST1968): Results with D1-3 q3wks schedule.
A. Fasolo
No relevant relationships to disclose
G. Del Conte
No relevant relationships to disclose
R. G. Calderone
No relevant relationships to disclose
E. Gallerani
No relevant relationships to disclose
N. Hagner
No relevant relationships to disclose
P. Barbieri
Employment or Leadership Position - Sigma-Tau
L. Luraghi
Employment or Leadership Position - Sigma-Tau
S. Pace
Employment or Leadership Position - Sigma-Tau
F. Capocasa
Employment or Leadership Position - Sigma-Tau
N. Coceani
Employment or Leadership Position - SENDO Tech
E. Maccioni
Employment or Leadership Position - SENDO Tech
D. Hess
No relevant relationships to disclose
C. Sessa
Consultant or Advisory Role - Sigma-Tau
Research Funding - Sigma-Tau
L. Gianni
Consultant or Advisory Role - Biogen Idec; Boehringer Ingelheim; Eisai; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi ; Takeda; Wyeth